BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Guo B, Wei J, Wang J, Sun Y, Yuan J, Zhong Z, Meng F. CD44-targeting hydrophobic phosphorylated gemcitabine prodrug nanotherapeutics augment lung cancer therapy. Acta Biomater 2022;145:200-9. [PMID: 35430336 DOI: 10.1016/j.actbio.2022.04.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Gong J, Shi T, Liu J, Pei Z, Liu J, Ren X, Li F, Qiu F. Dual-drug codelivery nanosystems: An emerging approach for overcoming cancer multidrug resistance. Biomed Pharmacother 2023;161:114505. [PMID: 36921532 DOI: 10.1016/j.biopha.2023.114505] [Reference Citation Analysis]
2 Kohon AI, Man K, Mathis K, Webb J, Yang Y, Meckes B. Nanoparticle targeting of mechanically modulated glycocalyx. bioRxiv 2023:2023. [PMID: 36909503 DOI: 10.1101/2023.02.27.529887] [Reference Citation Analysis]
3 Guo B, Qu Y, Sun Y, Zhao S, Yuan J, Zhang P, Zhong Z, Meng F. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative "cold" triple-negative breast cancer. Bioact Mater 2023;25:61-72. [PMID: 36733927 DOI: 10.1016/j.bioactmat.2023.01.014] [Reference Citation Analysis]
4 Miao T, Chen F, Du L, Xiao W, Fu J. Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. Front Genet 2022;13:930826. [DOI: 10.3389/fgene.2022.930826] [Reference Citation Analysis]